MZ Solution Achieves Success in Developing Complex Decellularization Technology... Accelerates Entry into the '900 Trillion' Biomaterials Market

MGene Solution announced on the 24th that it has succeeded in developing a complex decellularization technology. According to the company, this technology is expected to be widely applicable in the development of biomaterials using various xenogeneic tissues.

The decellularization technology developed by MGene Solution can remove cell nuclei and DNA from xenogeneic meniscus tissues such as those from pigs, while maintaining the three-dimensional structure of the extracellular matrix.

Compared to soft tissues and blood vessels, xenogeneic meniscus has greater tissue thickness and density, which results in longer processing times when applying conventional decellularization technologies. Additionally, the original tissue is damaged, and the use of expensive enzymes and protease inhibitors is required, making large-scale production economically inefficient.

The complex decellularization technology developed by the research team minimizes the use of costly enzymes and protease inhibitors and shortens the reaction time. A company representative stated, “Through this, damage to the extracellular matrix and three-dimensional structure is minimized, and cells and DNA that can cause immune rejection reactions upon transplantation are effectively removed.”

Furthermore, verification results showed that no cell nuclei were found in the tissue after decellularization, and the residual DNA concentration met the decellularization standard at 50 ng/mg or less.

A company representative said, “According to the U.S. National Institutes of Health (NIH), meniscus injuries occur in about 60 people per 100,000 and are common diseases, with surgical procedures currently being mainly used,” adding, “However, these treatments have limitations in fully restoring and regenerating meniscus function and preventing osteoarthritis.”

They continued, “In particular, transplantation has very limited availability of allografts and carries potential risks such as infection and immune rejection reactions.”

MGene Solution is preparing to file a patent application related to this complex decellularization technology. After completing additional safety and biomechanical evaluations, the company plans to conduct animal efficacy evaluations and tests for approval by the Korean Ministry of Food and Drug Safety within next year.

A company representative stated, “According to the market research firm BIS Research, the biomaterials development market is expected to reach $725.8 billion (approximately 942 trillion KRW) by 2031,” adding, “The complex decellularization technology can be utilized in the development of tissue regeneration biomaterials using various xenogeneic tissues.”

They also expressed expectations that it will greatly contribute to improving the quality of life for patients suffering from meniscus injuries.